The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...
Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.
The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1.
The move comes amid HHS Secretary Robert F. Kennedy Jr.’s decision to force out the top official responsible for reviewing such vaccines, Dr. Peter Marks, and put his deputy Julie Tierney on ...
The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, ...
“As of Tuesday, April 1, we had responded to all of the FDA’s information requests and we believe that our [Biologics License Application] is ready for approval,” Novavax said in a ...